ArticleFrontiers in pharmacology2023
A novel T-cell exhaustion-related feature can accurately predict the prognosis of OC patients.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 40 citations in OpenAlex.
- Pan-cancer prioritization of CCDC69 reveals an immune-enriched and therapeutically sensitive breast cancer phenotype.Discover oncology · 2026Article
- Integrative biomarker and drug target discovery in osteosarcoma: traditional experimental approaches and AI-enabled insights.Frontiers in pharmacology · 2026Review
- Bibliometric analysis of immune-related acute kidney injury induced by cancer immunotherapy (2000-2025).Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Charting the growth of programmed cell death studies in uveal melanoma: a bibliometric evidence.Discover oncology · 2025Article
- Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis.Human vaccines & immunotherapeutics · 2025Article
- Prognostic role and mutational characteristics of N6-methyladenosine-related genes in lung adenocarcinoma.Oncology letters · 2025Article
- A bibliometric study on microenvironment-mediated drug resistance in interventional liver cancer treatment.Discover oncology · 2025Article
- Article
- Article
- Combined preoperative platelet-albumin ratio and cancer inflammation prognostic index predicts prognosis in colorectal cancer: a retrospective study.Scientific reports · 2025Article
- Multi-Omics Analysis and Real-World Data Validation of Serine Metabolism-Related Genes in Colorectal Cancer.Journal of cellular and molecular medicine · 2025Article
- A four gene risk score model for prognosis and immune microenvironment insights in small cell lung cancer based on CAF functional-related genes.Discover oncology · 2025Article
- Machine Learning-Based Glycolipid Metabolism Gene Signature Predicts Prognosis and Immune Landscape in Oesophageal Squamous Cell Carcinoma.Journal of cellular and molecular medicine · 2025Article
- Neurotrophin NGF/TrkA and BDNF/TrkB signaling orchestrates the immune microenvironment in osteosarcoma.Frontiers in immunology · 2025Review
- Targeting tumor-associated macrophages in colon cancer: mechanisms and therapeutic strategies.Frontiers in immunology · 2025Review
- Integrating single-cell sequencing and transcriptome analysis to unravel the mechanistic role of sialylation-related genes in sepsis-induced acute respiratory distress syndrome.Frontiers in immunology · 2025Article
- Polypharmacy, drug-drug interactions and adverse drug reactions in older Chinese cancer patients: evidence from CHARLS.Frontiers in pharmacology · 2025Article
- Leveraging artificial intelligence to validate traditional biomarkers and drug targets in liver cancer recovery: a mini review.Frontiers in pharmacology · 2025Review
- Pre-operative habitual dietary fibre stratifies 12-week immune-inflammatory recovery after oesophagectomy: a multicentre prospective cohort study.Frontiers in nutrition · 2025Article
- NGF/BDNF-Trk/p75NTR signaling in osteosarcoma immunity: biomarkers and therapeutic opportunities.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phenomenon of T Cell exhaustion (TEX) entails a progressive deterioration in the functionality of T cells within the immune system during prolonged conflicts with chronic infections or tumors. In the context of ovarian cancer immunotherapy, the development, and outcome of treatment are closely linked to T-cell exhaustion. Hence, gaining an in-depth understanding of the features of TEX within the immune microenvironment of ovarian cancer is of paramount importance for the management of OC patients. To this end, we leveraged single-cell RNA data from OC to perform clustering and identify T-cell marker genes utilizing the Unified Modal Approximation and Projection (UMAP) approach. Through GSVA and WGCNA in bulk RNA-seq data, we identified 185 TEX-related genes (TEXRGs). Subsequently, we transformed ten machine learning algorithms into 80 combinations and selected the most optimal one to construct TEX-related prognostic features (TEXRPS) based on the mean C-index of the three OC cohorts. In addition, we explored the disparities in clinicopathological features, mutational status, immune cell infiltration, and immunotherapy efficacy between the high-risk (HR) and low-risk (LR) groups. Upon the integration of clinicopathological features, TEXRPS displayed robust predictive power. Notably, patients in the LR group exhibited a superior prognosis, higher tumor mutational load (TMB), greater immune cell infiltration abundance, and enhanced sensitivity to immunotherapy. Lastly, we verified the differential expression of the model gene CD44 using qRT-PCR. In conclusion, our study offers a valuable tool to guide clinical management and targeted therapy of OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.